A detailed history of Jpmorgan Chase & CO transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 21,771 shares of LRMR stock, worth $137,810. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,771
Previous 18,346 18.67%
Holding current value
$137,810
Previous $133,000 6.77%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$6.3 - $10.68 $21,577 - $36,579
3,425 Added 18.67%
21,771 $142,000
Q2 2024

Aug 12, 2024

SELL
$6.33 - $9.89 $636,424 - $994,350
-100,541 Reduced 84.57%
18,346 $133,000
Q1 2024

May 10, 2024

BUY
$4.2 - $13.28 $245,217 - $775,352
58,385 Added 96.5%
118,887 $902,000
Q4 2023

Feb 12, 2024

BUY
$2.35 - $4.71 $77,063 - $154,455
32,793 Added 118.35%
60,502 $275,000
Q3 2023

Nov 14, 2023

SELL
$3.08 - $4.49 $105,631 - $153,989
-34,296 Reduced 55.31%
27,709 $109,000
Q2 2023

Aug 11, 2023

SELL
$3.13 - $5.27 $1.91 Million - $3.21 Million
-609,852 Reduced 90.77%
62,005 $194,000
Q1 2023

May 11, 2023

BUY
$4.0 - $6.68 $2.51 Million - $4.19 Million
627,067 Added 1400.02%
671,857 $3.04 Million
Q4 2022

Feb 13, 2023

BUY
$2.73 - $5.08 $119,202 - $221,813
43,664 Added 3877.8%
44,790 $185,000
Q3 2022

Nov 14, 2022

SELL
$1.53 - $3.64 $1,343 - $3,195
-878 Reduced 43.81%
1,126 $4,000
Q2 2022

Aug 11, 2022

SELL
$1.9 - $3.98 $184 - $386
-97 Reduced 4.62%
2,004 $4,000
Q1 2022

May 11, 2022

BUY
$3.65 - $10.84 $1,908 - $5,669
523 Added 33.14%
2,101 $9,000
Q4 2021

Feb 10, 2022

BUY
$8.86 - $13.47 $4,128 - $6,277
466 Added 41.91%
1,578 $17,000
Q3 2021

Nov 12, 2021

BUY
$9.61 - $15.11 $10,686 - $16,802
1,112 New
1,112 $13,000

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $274M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.